Five Prime Therapeutics Aktie - FPRX

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

38,00

Gebot

38,01

Fragen

38,00

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

38,00

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif., April...

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call...

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality...

Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday...

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D...

Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D...

Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D...

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression & Reinforce Potential of Bemari...

All three efficacy endpoints (PFS, OS and ORR) in the FIGHT Phase 2 trial met pre-specified statistical significance 2021 priorities for the...

Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointe...

Detailed results of the Phase 2 FIGHT trial have been accepted for late breaker presentation during the Esophageal and Gastric cancer oral...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

FPRX - Frequently Asked Questions (FAQ)

What is the current Five Prime Therapeutics share price?

The current share price of Five Prime Therapeutics is US$ 38,00

What is the 1 year trading range for Five Prime Therapeutics share price?

Five Prime Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
JTAIJet AI Inc	US$ 6,02 (133,33%)	101,64M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	248,48M
WRDWeRide Inc	US$ 31,4877 (83,39%)	20,57M
INLFINLIF Limited	US$ 16,27 (80,58%)	7,67M
MBRXMoleculin Biotech Inc	US$ 2,1201 (66,94%)	134,88M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3,08 (-56,31%)	425,19k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3,36 (-52,68%)	5,21k
CSAICloudastructure Inc	US$ 19,0001 (-49,58%)	1,01M
NEXNNexxen International Ltd	US$ 10,30 (-49,16%)	160,99k
BSLKBolt Projects Holdings Inc	US$ 0,6626 (-46,13%)	13,07M
CNSPCNS Pharmaceuticals Inc	US$ 0,1415 (31,26%)	480,49M
MGOLMGO Global Inc	US$ 0,7176 (-15,08%)	411,17M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	248,48M
INTCIntel Corporation	US$ 23,60 (-2,20%)	225,04M
NVDANVIDIA Corporation	US$ 138,85 (2,63%)	189,56M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Five Prime Therapeutics Inc (FPRX)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

FPRX Neueste Nachrichten

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression & Reinforce Potential of Bemari...

Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointe...

FPRX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Five Prime Therapeutics Inc (FPRX) Börsenkurse

Five Prime Therapeutics Inc (FPRX)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

FPRX Neueste Nachrichten

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression & Reinforce Potential of Bemari...

Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointe...

FPRX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS